Download PDF
Thromb Haemost 1992; 68(06): 662-666
DOI: 10.1055/s-0038-1646340
Original Article
Schattauer GmbH Stuttgart

Expression of Urokinase and Its Receptor in Invasive and Non-Invasive Prostate Cancer Cell Lines

W Hollas
1   The Department of Tumor Biology, M. D. Anderson Cancer Center, Houston, TX, USA
,
N Hoosein
2   The Urology Research Laboratory, M. D. Anderson Cancer Center, Houston, TX, USA
,
L W K Chung
2   The Urology Research Laboratory, M. D. Anderson Cancer Center, Houston, TX, USA
,
A Mazar
3   The Thrombolytics Venture Abbott Labs, Abbott Park, IL, USA
,
J Henkin
3   The Thrombolytics Venture Abbott Labs, Abbott Park, IL, USA
,
K Kariko
4   The Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
,
E S Barnathan
4   The Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
,
D Boyd
1   The Department of Tumor Biology, M. D. Anderson Cancer Center, Houston, TX, USA
› Author Affiliations
Further Information

Publication History

Received 21 January 1992

Accepted after revision 03 July 1992

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We previously reported that extracellular matrix invasion by the prostate cancer cell lines, PC-3 and DU-145 was contingent on endogenous urokinase being bound to a specific cell surface receptor. The present study was undertaken to characterize the expression of both urokinase and its receptor in the non-invasive LNCaP and the invasive PC-3 and DU-145 prostate cells. Northern blotting indicated that the invasive PC-3 cells, which secreted 10 times more urokinase (680 ng/ml per 106 cells per 48 h) than DU-145 cells (63 ng/ml per 106 cells per 48 h), had the most abundant transcript for the plasminogen activator. This, at least, partly reflected a 3 fold amplification of the urokinase gene in the PC-3 cells. In contrast, urokinase-specific transcript could not be detected in the non-invasive LNCaP cells previously characterized as being negative for urokinase protein. Southern blotting indicated that this was not a consequence of deletion of the urokinase gene. Crosslinking of radiolabelled aminoterminal fragment of urokinase to the cell surface indicated the presence of a 51 kDa receptor in extracts of the invasive PC-3 and DU-145 cells but not in extracts of the non-invasive LNCaP cells. The amount of binding protein correlated well with binding capacities calculated by Scatchard analysis. In contrast, the steady state level of urokinase receptor transcript was a poor predictor of receptor display. PC-3 cells, which were equipped with 25,000 receptors per cell had 2.5 fold more steady state transcript than DU-145 cells which displayed 93,000 binding sites per cell.

 

  • REFERENCES

  • 1 Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990; 9: 353-367
    CrossrefPubMedGoogle Scholar
  • 2 Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65
    PubMedGoogle Scholar
  • 3 Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 4 Robbins KC, Summaria L, Hsieh B, Shah R. The peptide chains of human plasmin. J Biol Chem 1967; 242: 2333-2342
    PubMedGoogle Scholar
  • 5 Liotta L, Goldfarb R, Brundage R, Siegel G, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-4636
    PubMedGoogle Scholar
  • 6 Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001
    PubMedGoogle Scholar
  • 7 Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991; 3: 255-264
    PubMedGoogle Scholar
  • 8 Stoppelli MP, Tacchetti C, Cubellis M, Corti A, Hearing V, Cassani G, Appella E, Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675-684
    CrossrefPubMedGoogle Scholar
  • 9 Vassalli J, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92
    CrossrefPubMedGoogle Scholar
  • 10 Stoppelli MP, Corti A, Soffientini A, Cassanni G, Blasi F, Assoian R. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Nat Acad Sci USA 1985; 82: 4939-4943
    CrossrefPubMedGoogle Scholar
  • 11 Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem 1985; 260: 12382-12389
    PubMedGoogle Scholar
  • 12 Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-2445
    CrossrefPubMedGoogle Scholar
  • 13 Kirchheimer J, Remold H. Endogenous receptor bound urokinase mediates tissue invasion of human monocytes. J Immunol 1989; 143: 2634-2639
    PubMedGoogle Scholar
  • 14 Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991; 51: 3690-3695
    PubMedGoogle Scholar
  • 15 Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. J Biol Chem 1991; 266: 12, 752-758
    PubMedGoogle Scholar
  • 16 Boyd D, Ziober B, Chakrabarty S, Brattain MG. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res 1989; 49: 816-820
    PubMedGoogle Scholar
  • 17 Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly (A+) RNA. Proc Nat Acad Sci USA 1984; 81: 4727-4731
    CrossrefPubMedGoogle Scholar
  • 18 Roldan A, Cubellis M, Masucci M, Behrendt N, Lund L, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-474
    PubMedGoogle Scholar
  • 19 Barnathan E, Kuo A, Kariko K, Rosenfeld L, Murray S, Behrendt N, Ronne E, Weiner D, Henkin J, Cines D. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 1990; 76: 1795-1806
    PubMedGoogle Scholar
  • 20 Nielsen L, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000–60,000 Mr receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988; 263: 2358-2363
    PubMedGoogle Scholar
  • 21 Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines D. Interaction of single chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990; 265: 2865-2872
    PubMedGoogle Scholar
  • 22 Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Research 1985; 13: 2759-2771
    CrossrefPubMedGoogle Scholar
  • 23 Appella E, Robinson E, Ullrich S, Stoppelli M, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. J Biol Chem 1987; 262: 4437-4440
    PubMedGoogle Scholar
  • 24 Camiolo S, Markus G, Englander L, Siuta M, Hobika G, Kohga S. Plasminogen activator content and secretion in explants of neoplastic and benign prostate tissues. Cancer Res 1984; 44: 311-318
    PubMedGoogle Scholar
  • 25 Gaylis F, Keer H, Wilson M, Kwaan H, Sinha A, Kozlowski J. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989; 142: 193-198
    CrossrefPubMedGoogle Scholar
  • 26 Kaighn ME, Narayan K, Ohnuki Y, Lechner JK, Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23
    PubMedGoogle Scholar
  • 27 Cannio R, Rennie P, Blasi F. A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. Nucleic Acids Res 1991; 19: 2303-2308
    CrossrefPubMedGoogle Scholar